Ipca Laboratories Limited

BSE:524494 Stock Report

Market Cap: ₹479.6b

Ipca Laboratories Past Earnings Performance

Past criteria checks 4/6

Ipca Laboratories's earnings have been declining at an average annual rate of -2.2%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 13.4% per year. Ipca Laboratories's return on equity is 12.4%, and it has net margins of 11.8%.

Key information

-2.25%

Earnings growth rate

-2.07%

EPS growth rate

Pharmaceuticals Industry Growth17.49%
Revenue growth rate13.43%
Return on equity12.43%
Net Margin11.83%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ipca Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524494 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2696,47211,41121,8450
31 Dec 2595,0629,09921,5070
30 Sep 2593,5908,31720,9010
30 Jun 2591,5747,78720,6200
31 Mar 2589,4127,37720,0670
31 Dec 2487,2687,29519,7280
30 Sep 2485,3436,61219,4640
30 Jun 2482,1335,76818,6240
31 Mar 2477,0595,47417,3210
31 Dec 2371,8755,64315,9230
30 Sep 2366,8064,92214,5170
30 Jun 2362,5004,91113,4500
31 Mar 2362,4814,71313,1020
31 Dec 2260,2255,25012,7790
30 Sep 2259,0706,14212,4310
30 Jun 2258,5057,20512,2040
31 Mar 2258,3058,84111,9720
31 Dec 2156,5619,15211,5550
30 Sep 2156,3559,83711,1690
30 Jun 2154,52110,00510,7510
31 Mar 2154,20711,40010,3180
31 Dec 2053,80210,64710,1350
30 Sep 2051,8339,9689,9970
30 Jun 2051,0619,2289,7720
31 Mar 2046,4996,0639,3660
31 Dec 1944,5636,1898,9110
30 Sep 1942,4965,8048,4550
30 Jun 1939,7775,0598,2540
31 Mar 1937,7504,4488,1230
31 Mar 1832,8522,3947,6040
31 Mar 1731,5621,9457,1820
31 Mar 1628,6719316,4740

Quality Earnings: 524494 has high quality earnings.

Growing Profit Margin: 524494's current net profit margins (11.8%) are higher than last year (8.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524494's earnings have declined by 2.2% per year over the past 5 years.

Accelerating Growth: 524494's earnings growth over the past year (54.7%) exceeds its 5-year average (-2.2% per year).

Earnings vs Industry: 524494 earnings growth over the past year (54.7%) exceeded the Pharmaceuticals industry 15.9%.

Return on Equity

High ROE: 524494's Return on Equity (12.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/16 18:58
End of Day Share Price 2026/07/16 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ipca Laboratories Limited is covered by 38 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit Bhat360 ONE Capital Market Private Limited
Aditya KhemkaAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited